GlassScriptPhysician profile
Rowena Achin
NPI 1366467888
$5,954.17
in general payments reported to CMS, 2019-2025
39 companies · $2,033 in 2025
The $2,033 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $104 · 2021: $185 · 2022: $558 · 2023: $1,011 · 2024: $1,940 · 2025: $2,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,983.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,090.78 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $745.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $590.41 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $509.55 | 2022-2025 | |
| Amgen INC. | $392.08 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $335.93 | 2021-2025 | |
| Abbott Laboratories | $277.73 | 2023-2025 | Freestyle Libre 3, 2nd Gen Centrimag Primary Console, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.61 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.22 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $153.33 | 2022-2025 | Zoryve, Seglentis |
| Dexcom, INC. | $131.23 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $126.26 | 2022-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $105.51 | 2024-2025 | |
| Edwards Lifesciences Corporation | $104.68 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astellas Pharma US INC | $89.45 | 2022-2025 | Veozah |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rowena Achin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.